Israeli start-up C2i Genomics is sold to cancer diagnostics company Veracyte for up to USD95 million
Categories: Corporate and M&A, Hi-Tech
C2i Genomics is a minimal residual disease (MRD) cancer detection company.
The company’s whole-genome, artificial intelligence-powered approach generates broad signatures from blood more quickly and efficiently than bespoke panels. C2i Genomics MRD solution requires less than a tube of blood (as little as 3-4 ml blood, or 1-2 ml plasma), can go from sample to result in just two weeks, and delivers improved performance compared to imaging and other molecular tests.
Meitar and DLA advised Israeli startup C2i Genomics (the latter on the US aspects). Fenwick & West served as legal advisor for the Veracyte.
